Aspirin + Low‑Dose Rivaroxaban for Stable Atherosclerotic Disease

Indications & Clinical Efficacy

• In patients with stable coronary artery disease (CAD) or peripheral artery disease (PAD) who are at high ischemic risk and not at high bleeding risk, adding rivaroxaban 2.5 mg twice daily to aspirin 75‑100 mg once daily reduces major cardiovascular events. [@1]
• The COMPASS trial showed that this combination lowered the composite of cardiovascular death, myocardial infarction, and stroke with a number‑needed‑to‑treat of 77, while the number‑needed‑to‑harm for major bleeding was 84. [@1]
• All‑cause mortality was reduced by 23 % (hazard ratio 0.77; 95 % CI 0.65‑0.90) compared with aspirin alone. [@1]
• In PAD, the same regimen decreased major thrombotic vascular events, including acute limb ischemia and major amputation. [@1]

Subgroup Benefits

• Greater relative benefit observed in patients with diabetes mellitus, active smokers, and those older than 65 years. [@1]

Dosing Recommendations

• Standard regimen: aspirin 75‑100 mg once daily + riv‑aroxaban 2.5 mg twice daily (≈12 h apart). [@1]
• The 2.5 mg twice‑daily dose is the only approved dose for combination therapy in stable atherosclerotic disease; the 5 mg twice‑daily rivaroxaban monotherapy arm did not show benefit and is not recommended. [@1]

Bleeding Risk & Contra‑indications

• Major bleeding incidence rises from 1.9 %/year with aspirin alone to 3.1 %/year with the combination (hazard ratio 1.66). No significant increase in intracranial or fatal bleeding was observed. [@1]
• High‑bleeding‑risk (HBR) criteria in which the combination should be avoided include:

Special Clinical Scenarios

• Atrial fibrillation requiring anticoagulation: Use therapeutic‑dose rivaroxaban (15 mg daily, or 10 mg if CrCl 30‑49 mL/min) together with clopidogrel 75 mg daily without aspirin; limit triple therapy (rivaroxaban + aspirin + clopidogrel) to ≤1 week post‑PCI (standard risk) or up to 1 month (high ischemic risk). [@3]
• The low‑dose 2.5 mg twice‑daily rivaroxaban regimen is not approved for stroke prevention in atrial fibrillation. [@5]
• Moderate renal impairment (CrCl 30‑60 mL/min): No dose adjustment is required for the aspirin + riv‑aroxaban 2.5 mg BID regimen; relative risk reductions are preserved. [@1]
• Post‑PCI (without atrial fibrillation): Do not start the combination immediately; provide 6‑12 months of dual antiplatelet therapy (aspirin + clopidogrel) first, then consider transition to aspirin + riv‑aroxaban 2.5 mg BID if high ischemic risk and no HBR. [@1][@2]

Monitoring & Follow‑up

• Baseline laboratory assessment should include complete blood count (hemoglobin, platelets). [@3]
• Renal function should be re‑checked at least annually (more frequently if CrCl < 60 mL/min). [@3]
• Ongoing clinical reassessment of both bleeding and ischemic risk at each visit is essential. [@1]

Drug Interactions & Concomitant Medications

• Avoid concomitant non‑steroidal anti‑inflammatory drugs (NSAIDs) because they markedly increase bleeding risk.
• Strong dual CYP3A4 + P‑glycoprotein inhibitors (e.g., ketoconazole, ritonavir) are contraindicated; strong CYP3A4 inducers (e.g., rifampin) reduce rivaroxaban efficacy.
• Additional antiplatelet agents (clopidogrel, prasugrel, ticagrelor) should be used only when specifically indicated (e.g., recent ACS/PCI). [@3]

Duration of Therapy

• Continue the combination for as long as the patient remains at high ischemic risk without developing high bleeding risk or other contraindications; no predefined endpoint exists. Evidence beyond 3 years of follow‑up is lacking. [@1]

Situations in Which the Combination Should NOT Be Used

• Patients meeting any HBR criteria. [@1]
• Patients with atrial fibrillation who need anticoagulation for stroke prevention (use therapeutic‑dose rivaroxaban instead). [@3]
• Within the first 12 months after PCI (standard DAPT is recommended). [@2]
• CrCl < 15 mL/min. [@5]
• Active malignancy with high bleeding risk. [@1]
• When therapeutic anticoagulation for another indication is required.

Alternative Extended Antithrombotic Strategy

• Aspirin + ticagrelor 60 mg twice daily provides a comparable efficacy profile with a different bleeding pattern; both strategies are superior to aspirin alone in high‑risk patients, and the choice should be individualized based on comorbidities, bleeding history, medication burden, and patient preference. [@1][@2]

Guideline Recommendations for Combined Rivaroxaban, Aspirin, and Clopidogrel Therapy

1. Indications for Triple Therapy in Atrial Fibrillation (AF) After PCI

• In patients with AF who have undergone PCI, a short‑term triple regimen of rivaroxaban 15 mg once daily (or 10 mg if CrCl 30‑49 mL/min) + aspirin + clopidogrel is appropriate for up to 1 month after stent implantation, regardless of stent type. 1
• Extension of triple therapy to up to 6 months may be considered only for patients with a clearly higher ischemic risk (e.g., acute coronary syndrome presentation or complex anatomy) that outweighs bleeding risk. 1
• After the initial 1‑6 month period, aspirin should be stopped and patients should continue dual therapy with rivaroxaban 15 mg daily + clopidogrel 75 mg daily for the remainder of the first year post‑PCI. 1, 2
• At 12 months post‑PCI, clopidogrel should be discontinued and rivaroxaban monotherapy (15‑20 mg daily) continued for stroke prevention in AF. 1
• When rivaroxaban is combined with antiplatelet agents in AF, the 15 mg dose (instead of the standard 20 mg) is recommended. 1

2. Alternative Dual Therapy (Omitting Aspirin)

• For AF patients in whom bleeding risk outweighs ischemic risk, dual therapy with rivaroxaban 15 mg daily + clopidogrel 75 mg daily can replace the 1‑month triple regimen, thereby omitting aspirin from the start. 1, 2

3. Low‑Dose Rivaroxaban for Stable Atherosclerotic Disease (No AF)

• In patients with stable coronary or peripheral artery disease at high ischemic risk and no AF, the combination of rivaroxaban 2.5 mg twice daily + aspirin 75‑100 mg daily is indicated. 3
• Clopidogrel should not be added to this regimen outside the immediate post‑PCI window (first 6‑12 months). 3
• In the COMPASS trial, this low‑dose regimen reduced major cardiovascular events with a number‑needed‑to‑treat of 77 and a number‑needed‑to‑harm for major bleeding of 84. 3

4. Bleeding Risk Associated with Triple Therapy

• Over a 90‑day period, triple therapy (rivaroxaban + aspirin + clopidogrel) increased bleeding risk compared with oral anticoagulation + single antiplatelet therapy (hazard ratio 1.47; 95 % CI 1.04‑2.08). 1
• Triple therapy that uses rivaroxaban 2.5 mg BID (instead of warfarin) shows a lower bleeding risk than warfarin‑based triple therapy, though a significant hemorrhagic risk remains. 2, 4, 5

5. Contraindicated Antiplatelet Agents and Dosing Confusion

• Ticagrelor and prasugrel should not be used as part of triple therapy with rivaroxaban; only clopidogrel has sufficient safety data. 1, 6
• Do not confuse dosing regimens:
  
  • 15 mg once daily – for AF stroke prevention when combined with antiplatelet agents.
  • 2.5 mg twice daily – for stable atherosclerotic disease combined with aspirin (not for AF). 1, 2, 3

6. Duration Limits for Triple Therapy

• Prolonged triple therapy beyond the specified short‑term window markedly increases bleeding without proven additional ischemic benefit. 1, 7
• In AF patients post‑PCI, aspirin should not be added to rivaroxaban + clopidogrel beyond 1 month unless a documented very high ischemic risk clearly outweighs bleeding risk. 1

7. Practical Algorithm (European Society of Cardiology)

• AF patients:
  
  • ≤ 1 month post‑PCI: rivaroxaban 15 mg daily + aspirin + clopidogrel (triple therapy). 1
  • 1‑12 months post‑PCI: rivaroxaban 15 mg daily + clopidogrel (aspirin discontinued). 1, 2
  • > 12 months: rivaroxaban 15‑20 mg daily alone (all antiplatelets stopped). 1
• Patients without AF:
  
  • > 12 months after PCI and high ischemic risk: aspirin 75‑100 mg daily + rivaroxaban 2.5 mg BID (no clopidogrel). 3

8. Monitoring and Supportive Measures

• Bleeding and ischemic risk should be reassessed at every clinical visit to guide therapy adjustments. 3
• Proton‑pump inhibitor therapy is recommended for patients with gastrointestinal bleeding risk factors while on combined antithrombotic regimens. 6